Background

Epidemiology

Anatomy

Pathophysiology

Etiology

Genetics

Prognostic Factors

Clinical History

Physical Examination

Age group

Associated comorbidity

Associated activity

Acuity of presentation

Differential Diagnoses

Laboratory Studies

Imaging Studies

Procedures

Histologic Findings

Staging

Treatment Paradigm

by Stage

by Modality

Chemotherapy

Radiation Therapy

Surgical Interventions

Hormone Therapy

Immunotherapy

Hyperthermia

Photodynamic Therapy

Stem Cell Transplant

Targeted Therapy

Palliative Care

Medication

rezafungin

Indicated for the treatment of candidemia and invasive candidiasis in individuals with few or no therapeutic alternatives:

400mg Intravenous for one dose, then
200mg Intravenous every week
Safety and effectiveness beyond four weekly dosages are not known

Dose Adjustments

Renal Impairment
All levels of severity (CrCl >9.3 mL/min): No need to change the dose Undergoing Haemodialysis: No effects are anticipated

Hepatic Impairment
Child-Pugh A, B, or C severities: No need to change the dose

rezafungin

Indicated for the treatment of candidemia and invasive candidiasis in individuals with few or no therapeutic alternatives
:

400mg Intravenous for one dose, then
200mg Intravenous every week
Safety and effectiveness beyond four weekly dosages are not known

Dose Adjustments

Renal Impairment
All levels of severity (CrCl >9.3 mL/min): No need to change the dose Undergoing Haemodialysis: No effects are anticipated

Hepatic Impairment
Child-Pugh A, B, or C severities: No need to change the dose

rezafungin

Indicated for the treatment of candidemia and invasive candidiasis in individuals with few or no therapeutic alternatives
:

400mg Intravenous for one dose, then
200mg Intravenous every week
Safety and effectiveness beyond four weekly dosages are not known

Dose Adjustments

Renal Impairment
All levels of severity (CrCl >9.3 mL/min): No need to change the dose Undergoing Haemodialysis: No effects are anticipated

Hepatic Impairment
Child-Pugh A, B, or C severities: No need to change the dose

rezafungin

Indicated for the treatment of candidemia and invasive candidiasis in individuals with few or no therapeutic alternatives
:

400mg Intravenous for one dose, then
200mg Intravenous every week
Safety and effectiveness beyond four weekly dosages are not known

Dose Adjustments

Renal Impairment
All levels of severity (CrCl >9.3 mL/min): No need to change the dose Undergoing Haemodialysis: No effects are anticipated

Hepatic Impairment
Child-Pugh A, B, or C severities: No need to change the dose

nystatin topical

Mucocutaneous infection
Apply to the afflicted region every 8 to 12 hours until complete healing or as directed.

Vaginal Infections
Insert one tablet every night before sleep until healing is complete or as directed.

sulfanilamide

It is indicated in the treatment for Candida Vulvovaginitis
For thirty days, inject one applicatorful (approximately 6 g) up to two times daily intravaginally

Dose Adjustments

Limited data is available

miconazole nitrate/hydrocortisone

Apply cream topically over the affected part twice daily for one week
indications: it is indicated in the treatment of candidal intertrigo

nystatin topical

Mucocutaneous infection
Apply to the afflicted region every 8 to 12 hours until complete healing or as directed.

miconazole nitrate/hydrocortisone

For children above 10 years:
Apply cream topically over the affected part twice daily for one week
indications: it is used to treat candidal intertrigo

Future Trends